Univariate analysis of survival
| Prognostic factors . | No. patients . | EFS . | P . |
|---|---|---|---|
| Age | |||
| < 40 | 53 | 0.618 | |
| ≥ 40 | 12 | 0.583 | |
| < 40 vs ≥ 40 | .812 | ||
| Gender | |||
| Male | 39 | 0.629 | |
| Female | 26 | 0.577 | |
| Male vs female | .959 | ||
| Histology | |||
| NS/LP | 58 | 0.614 | |
| MC | 7 | 0.571 | |
| NS/LP vs MC | .714 | ||
| Relapse vs refractory | |||
| Rel | 43 | 0.653 | |
| Ref | 22 | 0.524 | |
| Rel vs ref | .051 | ||
| Ref/rel < 1 y | 35 | 0.428 | |
| Rel > 1 y | 30 | 0.807 | |
| Ref/rel < 1 y vs rel > 1 y | .001 | ||
| Radiation treatment | |||
| No prior RT | 26 | 0.559 | |
| Prior RT | 39 | 0.641 | |
| No prior RT vs prior RT | .756 | ||
| B symptoms pre-ICE | |||
| −B symp | 49 | 0.729 | |
| +B symp | 16 | 0.225 | |
| −B symp vs +B symp | < .001 | ||
| Extranodal disease pre-ICE | |||
| +ENS | 33 | 0.818 | |
| −ENS | 32 | 0.392 | |
| +ENS vs −ENS | < .001 |
| Prognostic factors . | No. patients . | EFS . | P . |
|---|---|---|---|
| Age | |||
| < 40 | 53 | 0.618 | |
| ≥ 40 | 12 | 0.583 | |
| < 40 vs ≥ 40 | .812 | ||
| Gender | |||
| Male | 39 | 0.629 | |
| Female | 26 | 0.577 | |
| Male vs female | .959 | ||
| Histology | |||
| NS/LP | 58 | 0.614 | |
| MC | 7 | 0.571 | |
| NS/LP vs MC | .714 | ||
| Relapse vs refractory | |||
| Rel | 43 | 0.653 | |
| Ref | 22 | 0.524 | |
| Rel vs ref | .051 | ||
| Ref/rel < 1 y | 35 | 0.428 | |
| Rel > 1 y | 30 | 0.807 | |
| Ref/rel < 1 y vs rel > 1 y | .001 | ||
| Radiation treatment | |||
| No prior RT | 26 | 0.559 | |
| Prior RT | 39 | 0.641 | |
| No prior RT vs prior RT | .756 | ||
| B symptoms pre-ICE | |||
| −B symp | 49 | 0.729 | |
| +B symp | 16 | 0.225 | |
| −B symp vs +B symp | < .001 | ||
| Extranodal disease pre-ICE | |||
| +ENS | 33 | 0.818 | |
| −ENS | 32 | 0.392 | |
| +ENS vs −ENS | < .001 |
EFS indicates event-free survival; NS/LP, nodular sclerosis/lymphocytic predominance; MC, mixed cellularity; rel, relapse; ref, refractory; RT, radiation treatment; ICE, ifosfamide, carboplatin, and etoposide; symp, symptoms; ENS, extranodal disease.